Quia Pharma Past Earnings Performance
Past criteria checks 0/6
Quia Pharma has been growing earnings at an average annual rate of 5.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 6.9% per year.
Key information
5.2%
Earnings growth rate
48.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 6.9% |
| Return on equity | -40.0% |
| Net Margin | -277.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Quia Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5 | -14 | 13 | 0 |
| 31 Mar 24 | 5 | -15 | 14 | 0 |
| 31 Dec 23 | 4 | -17 | 14 | 0 |
| 30 Sep 23 | 4 | -18 | 14 | 0 |
| 30 Jun 23 | 5 | -20 | 15 | 0 |
| 31 Mar 23 | 5 | -20 | 15 | 0 |
| 31 Dec 22 | 6 | -20 | 16 | 0 |
| 30 Sep 22 | 6 | -22 | 17 | 0 |
| 30 Jun 22 | 6 | -22 | 17 | 0 |
| 31 Mar 22 | 7 | -22 | 17 | 0 |
| 31 Dec 21 | 9 | -20 | 16 | 0 |
| 30 Sep 21 | 8 | -20 | 16 | 0 |
| 30 Jun 21 | 6 | -24 | 19 | 0 |
| 31 Mar 21 | 6 | -26 | 20 | 0 |
| 31 Dec 20 | 4 | -28 | 21 | 0 |
| 30 Sep 20 | 5 | -28 | 23 | 0 |
| 30 Jun 20 | 5 | -24 | 21 | 0 |
| 31 Mar 20 | 4 | -22 | 21 | 0 |
| 31 Dec 19 | 4 | -20 | 20 | 0 |
| 30 Sep 19 | 1 | -19 | 16 | 0 |
| 30 Jun 19 | 2 | -15 | 14 | 0 |
| 31 Mar 19 | 3 | -14 | 15 | 0 |
| 31 Dec 18 | 3 | -12 | 14 | 0 |
| 30 Sep 18 | 8 | -7 | 14 | 0 |
| 30 Jun 18 | 7 | -7 | 12 | 0 |
| 31 Mar 18 | 5 | -5 | 8 | 0 |
| 31 Dec 17 | 4 | -4 | 8 | 0 |
| 31 Dec 16 | 2 | -2 | 3 | 0 |
Quality Earnings: 99B0 is currently unprofitable.
Growing Profit Margin: 99B0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 99B0 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.
Accelerating Growth: Unable to compare 99B0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 99B0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: 99B0 has a negative Return on Equity (-39.97%), as it is currently unprofitable.